Key Highlights

  • Abbott's $0.63 quarterly dividend has an October 15, 2026 ex-dividend date and is payable November 16 to shareholders of record.
  • The company describes it as its 411th consecutive quarterly dividend and states it has increased its payout for 54 consecutive years.
  • Second-quarter sales rose 13.0% on a reported basis and 4.8% on a comparable basis, with GAAP diluted EPS of $0.53.
  • Adjusted diluted EPS was $1.31, and full-year adjusted EPS guidance was raised to $5.45 to $5.60.

Abbott Laboratories' (NYSE:ABT) $0.63 quarterly dividend yields 2.46% and sits beside second-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31. The board declared it on September 17, 2026, matching the $0.63 declared on June 12, 2026. The company states that it has increased its dividend payout for 54 consecutive years.

Dividend Program and Shareholder Returns

Abbott's board declared a quarterly common dividend of 63 cents per share on September 17, 2026. It is payable November 16 to shareholders of record at the close of business on October 15. The company describes it as the 411th consecutive quarterly dividend.

The June 12 declaration of $0.63 was the 410th, payable August 17 to shareholders of record on July 15.

The company states that it is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased their dividend for at least 25 consecutive years. It also reported returning $2.1 billion to shareholders in the second quarter through dividends and share repurchases.

About the Company

Abbott is a global healthcare company headquartered in Abbott Park, Illinois. Its portfolio spans diagnostics, medical devices, nutritionals and branded generic medicines. The company states that its 122,000 colleagues serve people in more than 160 countries.

Financial Performance Behind the Payout

Abbott reported second-quarter sales of $12.6 billion ($12,593 million) for the quarter ended June 30, 2026, up 13.0% on a reported basis from $11,142 million and 4.8% on a comparable basis. GAAP diluted EPS was $0.53 versus $1.01. Adjusted diluted EPS, a non-GAAP measure that excludes specified items, was $1.31 versus $1.26. Net earnings were $928 million.

Medical Devices sales were $5,853 million, up 9.0% reported and 8.4% comparable, led by low-teens growth in Electrophysiology. Diagnostics sales were $3,092 million, up 42.3% reported and 2.9% comparable. Established Pharmaceuticals sales rose 8.4% reported.

Nutrition sales were $2,144 million, down 3.1% reported and 3.6% comparable. The company cited lower sales volumes and the effect of pricing actions implemented in the fourth quarter of 2025, and stated that Nutrition sales increased $127 million sequentially from the first quarter.

The Exact Sciences Acquisition Inside the Results

Abbott completed its acquisition of Exact Sciences on March 23, 2026. Exact Sciences sales are presented as Abbott's Cancer Diagnostics business, which reported second-quarter sales of $919 million, with Cologuard growing in the mid-teens. Abbott states that Exact Sciences had 2025 worldwide sales of $3.247 billion.

Comparable sales growth includes the prior and current year sales of Exact Sciences. Net interest expense was $299 million versus $50 million a year earlier, and specified items included $658 million of intangible amortization and $385 million of legal reserves related to an agreed-in-principle settlement.

Outlook

Abbott's 2026 guidance is adjusted diluted EPS of $5.45 to $5.60, raised from $5.38 to $5.58, and comparable sales growth of 6.5% to 7.5%, reaffirmed. Third-quarter adjusted diluted EPS guidance is $1.38 to $1.46. The company states it has not provided GAAP measures on a forward-looking basis.